Jul 27, 2018 Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering Learn More
Jul 18, 2018 Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients Learn More
Jul 17, 2018 Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study Learn More